Senti Biosciences (SNTI) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Senti Biosciences (SNTI) over the past year, losing 49.5% versus a loss of 81.9%. Over five years, SNTI leads with a -99.7% price change compared with -99.8% for TOVX. Theriva Biologics is the larger company by market cap ($10.1 million vs $9.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNTI | TOVX |
|---|---|---|
| Share price | $0.3149 | $0.2203 |
| Market cap | $9.81M | $10.11M |
| 1-day change | -2.11% | -2.99% |
| YTD return | -69.07% | +8.14% |
| 1-year return | -81.93% | -49.53% |
| 5-year return | -99.68% | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-1.72 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.88 | $0.86 |
| 52-week low | $0.29 | $0.16 |
| Distance from 52-week high | -89.07% | -74.38% |
| Analyst consensus | none | none |
| Avg. price target upside | +4187.08% | +1034.82% |
| Average volume | 573.78K | 525.96K |
| Shares outstanding | 31.15M | 45.89M |
| Employees | 39 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed SNTI by 32.4 percentage points over the past year.
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
SNTI vs TOVX FAQ
Which is bigger, Senti Biosciences or Theriva Biologics?
Theriva Biologics (TOVX) is larger, with a market capitalization of $10.11M compared with $9.81M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, SNTI or TOVX?
TOVX returned -49.53% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are Senti Biosciences and Theriva Biologics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Senti Biosciences and Biotechnology: Pharmaceutical Preparations for Theriva Biologics.